A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4(+) T-cell response

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4(+) T-cell response. / Karlsen, Kasper; Korsholm, Karen Smith; Mortensen, Rasmus; Ghiasi, Seyed Mojtaba; Andersen, Peter; Foged, Camilla; Christensen, Dennis.

I: Nanomedicine, Bind 9, Nr. 17, 12.2014, s. 2625-38.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Karlsen, K, Korsholm, KS, Mortensen, R, Ghiasi, SM, Andersen, P, Foged, C & Christensen, D 2014, 'A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4(+) T-cell response', Nanomedicine, bind 9, nr. 17, s. 2625-38. https://doi.org/10.2217/nnm.14.197

APA

Karlsen, K., Korsholm, K. S., Mortensen, R., Ghiasi, S. M., Andersen, P., Foged, C., & Christensen, D. (2014). A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4(+) T-cell response. Nanomedicine, 9(17), 2625-38. https://doi.org/10.2217/nnm.14.197

Vancouver

Karlsen K, Korsholm KS, Mortensen R, Ghiasi SM, Andersen P, Foged C o.a. A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4(+) T-cell response. Nanomedicine. 2014 dec.;9(17):2625-38. https://doi.org/10.2217/nnm.14.197

Author

Karlsen, Kasper ; Korsholm, Karen Smith ; Mortensen, Rasmus ; Ghiasi, Seyed Mojtaba ; Andersen, Peter ; Foged, Camilla ; Christensen, Dennis. / A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4(+) T-cell response. I: Nanomedicine. 2014 ; Bind 9, Nr. 17. s. 2625-38.

Bibtex

@article{ed14afc797e049c0b90887bf6813e0b8,
title = "A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4(+) T-cell response",
abstract = "AIM: To combine the dimethyldioctadecyl ammonium/monomycoloyl glycerol (DDA/MMG) liposomal vaccine adjuvant with the Toll-like receptor (TLR) ligands poly(I:C) (TLR3), flagellin (TLR5) or CpG oligodeoxynucleotide 1826 (TLR9) and investigate their physicochemical properties as well as their CD4(+) T-cell-inducing capacity.MATERIALS & METHODS: Formulations were investigated by dynamic light scattering and differential scanning calorimetry. Their CD4(+) T-cell induction with a tuberculosis antigen was analyzed by multiplex cytokine analysis, ELISA and intracellular cytokine staining.RESULTS: DDA/MMG/CpG was the best combination for obtaining increased CD4(+) T-cell responses. However, coformulating CpG and DDA/MMG liposomes led to instability and the formulation was therefore optimized systematically using a design of experiment.CONCLUSION: The nanoparticulate DDA/MMG/CpG adjuvant can be stabilized and synergistically enhances CD4(+) T-cell responses compared with DDA/MMG liposomes.",
author = "Kasper Karlsen and Korsholm, {Karen Smith} and Rasmus Mortensen and Ghiasi, {Seyed Mojtaba} and Peter Andersen and Camilla Foged and Dennis Christensen",
year = "2014",
month = dec,
doi = "10.2217/nnm.14.197",
language = "English",
volume = "9",
pages = "2625--38",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "17",

}

RIS

TY - JOUR

T1 - A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4(+) T-cell response

AU - Karlsen, Kasper

AU - Korsholm, Karen Smith

AU - Mortensen, Rasmus

AU - Ghiasi, Seyed Mojtaba

AU - Andersen, Peter

AU - Foged, Camilla

AU - Christensen, Dennis

PY - 2014/12

Y1 - 2014/12

N2 - AIM: To combine the dimethyldioctadecyl ammonium/monomycoloyl glycerol (DDA/MMG) liposomal vaccine adjuvant with the Toll-like receptor (TLR) ligands poly(I:C) (TLR3), flagellin (TLR5) or CpG oligodeoxynucleotide 1826 (TLR9) and investigate their physicochemical properties as well as their CD4(+) T-cell-inducing capacity.MATERIALS & METHODS: Formulations were investigated by dynamic light scattering and differential scanning calorimetry. Their CD4(+) T-cell induction with a tuberculosis antigen was analyzed by multiplex cytokine analysis, ELISA and intracellular cytokine staining.RESULTS: DDA/MMG/CpG was the best combination for obtaining increased CD4(+) T-cell responses. However, coformulating CpG and DDA/MMG liposomes led to instability and the formulation was therefore optimized systematically using a design of experiment.CONCLUSION: The nanoparticulate DDA/MMG/CpG adjuvant can be stabilized and synergistically enhances CD4(+) T-cell responses compared with DDA/MMG liposomes.

AB - AIM: To combine the dimethyldioctadecyl ammonium/monomycoloyl glycerol (DDA/MMG) liposomal vaccine adjuvant with the Toll-like receptor (TLR) ligands poly(I:C) (TLR3), flagellin (TLR5) or CpG oligodeoxynucleotide 1826 (TLR9) and investigate their physicochemical properties as well as their CD4(+) T-cell-inducing capacity.MATERIALS & METHODS: Formulations were investigated by dynamic light scattering and differential scanning calorimetry. Their CD4(+) T-cell induction with a tuberculosis antigen was analyzed by multiplex cytokine analysis, ELISA and intracellular cytokine staining.RESULTS: DDA/MMG/CpG was the best combination for obtaining increased CD4(+) T-cell responses. However, coformulating CpG and DDA/MMG liposomes led to instability and the formulation was therefore optimized systematically using a design of experiment.CONCLUSION: The nanoparticulate DDA/MMG/CpG adjuvant can be stabilized and synergistically enhances CD4(+) T-cell responses compared with DDA/MMG liposomes.

U2 - 10.2217/nnm.14.197

DO - 10.2217/nnm.14.197

M3 - Journal article

C2 - 25529567

VL - 9

SP - 2625

EP - 2638

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 17

ER -

ID: 129781428